1928-zT-2 (Guangzhou Institutes of Biomedicine and Health)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Name1928-zT-2 (Guangzhou Institutes of Biomedicine and Health)
Drug Alias Nameanti-CD19 CAR T-cell therapy (B-cell acute lymphoblastic leukemia)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A